Pathophysiology of neuronal energy crisis in Alzheimer's disease - PubMed (original) (raw)
Review
doi: 10.1159/000113681. Epub 2008 Mar 6.
Affiliations
- PMID: 18322369
- DOI: 10.1159/000113681
Review
Pathophysiology of neuronal energy crisis in Alzheimer's disease
Jack C de la Torre. Neurodegener Dis. 2008.
Abstract
A large body of evidence indicates that sporadic Alzheimer's disease (AD) is a vascular disorder with neurodegenerative consequences and needs to be treated and managed as such. Epidemiologic studies of vascular risk factors, together with preclinical detection tools for AD are proof of concept that cerebral hypoperfusion is one of the earliest pathological signs in the development of cognitive failure. Vascular risk factors involving heart disease and stroke in the elderly individual who already possesses a dwindling cerebrovascular reserve due to advancing age contribute to further decline in cerebral blood flow (CBF) resulting in unrelenting brain hypoperfusion. Brain hypoperfusion, in turn, can reach a critically attained threshold of cerebral hypoperfusion (CATCH) giving rise to a neuronal energy crisis via reduced ATP synthesis. The ensuing metabolic energy crisis initially carves up ischemic-sensitive neurons in the hippocampus and posterior parietal cortex setting up cognitive meltdown and progressive neurodegenerative and atrophic changes in the brain. Neuronal energy compromise accelerates oxidative stress, excess production of reactive oxygen species, aberrant protein synthesis, ionic membrane pump dysfunction, signal transduction impairment, neurotransmitter failure, abnormal processing of amyloid precursor protein resulting in beta-amyloid deposition and axonal microtubule disruption from tau hyperphosphorylation. The high energy metabolic changes leading to oxidative stress and cellular hypometabolism precede clinical expression of AD. Regional CBF measurements using neuroimaging techniques can predict AD preclinically at the mild cognitive impairment stage or even before any clinical manifestation of dementia is expressed. Clinical diagnostic assessment of elderly persons who could develop or already present with memory complaints can prevent, reverse or slow down AD development. Although pathologic aging is the subject of thousands of studies, the question of why the elderly (and not younger people) succumb to AD has not been adequately addressed. The explanation(s) as to why vascular risk factors, for example, can trigger AD or vascular dementia usually in the elderly and not the young should provide vital clues in the search for a strategically effective dementia treatment. This review offers inductive hypothetical darts relative to that critical question.
2008 S. Karger AG, Basel
Similar articles
- Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease.
Aliev G, Smith MA, de la Torre JC, Perry G. Aliev G, et al. Mitochondrion. 2004 Sep;4(5-6):649-63. doi: 10.1016/j.mito.2004.07.018. Mitochondrion. 2004. PMID: 16120422 - Cerebrovascular and cardiovascular pathology in Alzheimer's disease.
de la Torre JC. de la Torre JC. Int Rev Neurobiol. 2009;84:35-48. doi: 10.1016/S0074-7742(09)00403-6. Int Rev Neurobiol. 2009. PMID: 19501712 Review. - Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease.
Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich ME, Morales L. Aliev G, et al. Int J Biochem Cell Biol. 2009 Oct;41(10):1989-2004. doi: 10.1016/j.biocel.2009.03.015. Epub 2009 Apr 5. Int J Biochem Cell Biol. 2009. PMID: 19703659 Review. - [The role of chronic brain hypoperfusion in the pathogenesis of Alzheimer's disease--facts and hypotheses].
Zádori D, Datki Z, Penke B. Zádori D, et al. Ideggyogy Sz. 2007 Nov 30;60(11-12):428-37. Ideggyogy Sz. 2007. PMID: 18198789 Review. Hungarian. - Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S, Rauk A. Roy S, et al. Med Hypotheses. 2005;65(1):123-37. doi: 10.1016/j.mehy.2004.08.031. Med Hypotheses. 2005. PMID: 15893129
Cited by
- Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort.
Ziad A, Olekhnovitch R, Ruiz F, Berr C, Bégaud B, Goldberg M, Zins M, Mura T. Ziad A, et al. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1107-1115. doi: 10.1136/jnnp-2018-318190. Epub 2018 Sep 8. J Neurol Neurosurg Psychiatry. 2018. PMID: 30196250 Free PMC article. - The role of functional status on the relationship between blood pressure and cognitive decline: the Cardiovascular Health Study.
Miller LM, Peralta CA, Fitzpatrick AL, Wu C, Psaty BM, Newman AB, Odden MC. Miller LM, et al. J Hypertens. 2019 Sep;37(9):1790-1796. doi: 10.1097/HJH.0000000000002102. J Hypertens. 2019. PMID: 31058794 Free PMC article. - Pirh2 modulates the mitochondrial function and cytochrome c-mediated neuronal death during Alzheimer's disease.
Singh A, Tiwari S, Singh S. Singh A, et al. Cell Death Dis. 2024 May 13;15(5):331. doi: 10.1038/s41419-024-06662-1. Cell Death Dis. 2024. PMID: 38740775 Free PMC article. - Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice.
Wang P, Su C, Feng H, Chen X, Dong Y, Rao Y, Ren Y, Yang J, Shi J, Tian J, Jiang S. Wang P, et al. Int J Immunopathol Pharmacol. 2017 Mar;30(1):25-43. doi: 10.1177/0394632016688025. Epub 2017 Jan 26. Int J Immunopathol Pharmacol. 2017. PMID: 28124574 Free PMC article. - Mapping Age Differences in Brain Energy Metabolites and Metabolic Markers of Cellular Membrane Production and Degradation With 31P Magnetic Resonance Spectroscopy.
Raz N, Daugherty AM, Khatib D, Dahle CL, Rajan U, Zajac-Benitez C, Stanley JA. Raz N, et al. Hum Brain Mapp. 2024 Oct;45(14):e70039. doi: 10.1002/hbm.70039. Hum Brain Mapp. 2024. PMID: 39391993 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical